HOLOGIC INC
NASDAQ: HOLX (Hologic, Inc.)
Last update: 20 hours ago64.75
-0.47 (-0.72%)
| Previous Close | 65.22 |
| Open | 64.51 |
| Volume | 2,209,613 |
| Avg. Volume (3M) | 3,647,539 |
| Market Cap | 14,429,213,696 |
| Price / Earnings (TTM) | 27.21 |
| Price / Earnings (Forward) | 14.33 |
| Price / Sales | 3.74 |
| Price / Book | 3.12 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | 13.83% |
| Operating Margin (TTM) | 22.17% |
| Diluted EPS (TTM) | 2.38 |
| Quarterly Revenue Growth (YOY) | -1.20% |
| Quarterly Earnings Growth (YOY) | -18.50% |
| Total Debt/Equity (MRQ) | 54.80% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 1.13 B |
| Levered Free Cash Flow (TTM) | 775.88 M |
| Return on Assets (TTM) | 6.92% |
| Return on Equity (TTM) | 11.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Hologic, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 102.75% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 71.00 (Raymond James, 9.65%) | Buy |
| Median | 70.00 (8.11%) | |
| Low | 62.00 (Evercore ISI Group, -4.25%) | Hold |
| Average | 67.60 (4.40%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 54.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 13 May 2025 | 70.00 (8.11%) | Buy | 57.12 |
| Morgan Stanley | 05 May 2025 | 65.00 (0.39%) | Hold | 52.73 |
| Evercore ISI Group | 02 May 2025 | 62.00 (-4.25%) | Hold | 54.16 |
| RBC Capital | 02 May 2025 | 70.00 (8.11%) | Hold | 54.16 |
| Raymond James | 02 May 2025 | 71.00 (9.65%) | Buy | 54.16 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 May 2025 | Announcement | Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients |
| 13 May 2025 | Announcement | Hologic to Webcast Presentations at Upcoming Investor Conferences |
| 01 May 2025 | Announcement | Hologic Announces Financial Results for Second Quarter of Fiscal 2025 |
| 24 Apr 2025 | Announcement | Groundbreaking New Data on Hologic’s AI-Powered Mammography Technology to Be Presented at SBI |
| 22 Apr 2025 | Announcement | Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report |
| 04 Apr 2025 | Announcement | Wayde McMillan Elected to Hologic Board of Directors |
| 03 Apr 2025 | Announcement | Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |